Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs.

P N Elliott; P Jenner; C D Marsden

doi:10.1111/j.2042-7158.1978.tb13394.x

Home/Archive/PubMed

PubMed · 32246

Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs.

P N Elliott·P Jenner·C D Marsden

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

3,4-Dihydroxyphenylacetic Acid Animals Atropine Benzamides Brain Dopamine Drug Interactions Haloperidol Homovanillic Acid Male Mice Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P N Elliott, P Jenner, C D Marsden. 1978. Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs.. https://doi.org/10.1111/j.2042-7158.1978.tb13394.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1979

Dopamine metabolism, spiperone binding and adenylate cyclase activity in the adult rat hippocampus after ingrowth of dopaminergic neurones from embryonic implants.

The growth of dopamine (DA) neurones of rat embryonic mesencephalic brain tissue implanted close to the anterior part of the hippocampus of adult rats was studied by measuring the levels of DA and 3,4-dihydroxyphenylacetic acid (DOPAC) in the host hippocampus. The hippocampal levels of DA and DOPAC reached maximal values 6 months after transplantation. The neuroleptic drug haloperidol evoked an increase in the levels of DOPAC. No evidence was found for the induction of DA-sensitive adenylate cyclase activity or of binding sites of [3H]spiperone. These results indicate that there is a substantial ingrowth of transplanted DA neurones into the host hippocampus, but no evidence was found for the development of functional contacts between the embryonic DA neurons and the host tissue.

3,4-Dihydroxyphenylacetic Acid↗

PubMed1979

Analysis of the activation of dopamine metabolism by a serotonin uptake inhibitor.

The potentiation of the effect of haloperidol on rat striatal homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) by a serotonin (5-HT) uptake inhibitor, CGP 6085 A, has been further investigated. The evidence that this effect of CGP 6085 A is related to its 5-HT uptake inhibitory properties is discussed. The potentiation was antagonized by scopolamine and baclofen, and disappeared more rapidly than the uptake inhibitory effects of CGP 6085 A, presumably because the effects of uptake inhibition were counteracted by a reduction in 5-HT synthesis. CGP 6085 A also potentiated the effects of fluphenazine and pimozide, but not those of a number of other neuroleptics. It also failed to restore the effect of haloperidol in animals treated chronically with the neuroleptic. These results appear to indicate that CGP 6085 A can only stimulate DA neurons if their activity is already above the resting level. The antagonism of this effect by scopolamine suggests that the site of action of the 5-HT uptake inhibitor is before a cholinergic neuron.

3,4-Dihydroxyphenylacetic Acid↗

PubMed1979

Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.

Prolactin secretion inhibition and changes in striatal dopamine metabolism in rats were compared after the administration of 8 alpha-amino-ergoline CH 29-717 and 2 derivates. CQ 32-084 was similar to but less potent than CH 29-717, while 32-085, the l-methyl derivative, showed delayed dopaminomimetic effects.

3,4-Dihydroxyphenylacetic Acid↗